On 19 June, Nessa Childers MEP (S&D, Ireland) chaired a roundtable of stakeholders on Clinical Trials, brought together by the European Haemophilia Consortium. The meeting highlighted some of the specific issues related to haemophilia and reiterated some of the overarching challenges pertaining to the forthcoming revision of the Clinical Trials Directive.
As the European Commission continues to be engaged in inter-service consultations before the release of its legislative proposal in July 2012, the meeting served as a briefing for Members of the European Parliament (MEPs) and other stakeholders, including the European Medicines Agency, civil society and industry, to put into context some of the issues at stake (see also EPHA’s response to the 2011 consultation by the Commission).
The presentations served to work out some of the challenges that clinical trials are facing, especially in haemophilia. Some of the issues discussed were:
- the recruitment of a sufficiently high number of patients to obtain authorisation for the next generation of products. It concerns both adult and paediatric studies, previously untreated patients and those already treated. It was stressed that all of them should be compensated for the time (travel expenses and/or payments);
- easing multinational trials;
- ensuring access to treatment with new products; purchasing mechanisms;
- the use of biosimilars vs novel products.
Nessa Childers MEP pointed out that MEPs are dealing with ever increasing amounts of information and hence it will be important to focus on key political messages communicated in a clear and understandable fashion. She summarised some of the principal issues identified during the meeting as follows:
– Urgent need for elements of harmonisation (regarding CT applications, assessments, etc.) that will bring benefits for patients, industry and Member States.
– Reducing administrative burden and costs, shorter timelines for review.
– Multi-country trials: one Ethics Committee opinion per Member State (instead of allowing individual hospitals and/or different committees to issue conflicting opinions); improved interaction between Ethics Committee and National Competent Authorities.
– Harmonised assessment and approval process of study design.
MEP Childers also emphasised the importance of speaking with other stakeholders, including other patients groups, in order to frame cross-cutting messages with valuable examples for public health decision makers.
Three issues identified by participants that may cause controversy in the revision process include third country trials, transparency of CT data, and relinquishing specific national requirements.
—-
For further information
– DG SANCO – Clinical Trials webpages
EPHA related articles
– [->5115]
– [->5074]
– [->5063]
– [->5014]
– [->5000]
– [->4967]
– [->4782]
– [->4764]
